Implementation of point-of-care testing and a temporary influenza ward in a Dutch hospital

J.M. Lankelma¹, M.H.A. Hermans¹, E.H.L.C.M. Hazenberg¹, T. Macken², P.L.J. Dautzenberg¹, K.C.M.C. Koeijvoets⁴, J.W.H. Jaspers⁵, A.B. van Gageldonk-Lafeber⁶, S.P.M. Lutgens¹*¹

Departments of ¹Medical Microbiology, ²Pulmonology, ³Geriatrics, ⁴Emergency Medicine, Jeroen Bosch Hospital, ’s Hertogenbosch, the Netherlands; ⁵National Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands.
*Corresponding author: s.lutgens@jbz.nl

ABSTRACT

Background. The seasonal influenza epidemic poses a significant burden on hospitals, both in terms of capacity and costs. Beds that are occupied by isolated influenza patients result in hospitals temporary being closed to admissions and elective operations being cancelled. Improving hospital and emergency department (ED) patient flow during the influenza season could solve these problems. Microbiological point-of-care-testing (POCT) could reduce unnecessary patient isolation by providing a positive/negative result before admission, but has not yet broadly been implemented.

Methods. A clinical pathway for patients with acute respiratory tract infection presenting at the ED was implemented, including a PCR-based POCT for influenza, operated by nurses and receptionists. In parallel, a temporary ward equipped with 15 beds for influenza-positive patients was established. In this retrospective observational study, we describe the results of implementing this pathway by comparison with the previous epidemic.

Results. Clinical performance of the POCT within the clinical pathway was good with strongly decreased time from ED presentation to sample collection (194 vs 47 min) and time from sample collection to result (1094 vs 62 min). Hospital patient flow was improved by a decreased percentage of admitted influenza-positive patients (91% vs 73%) and shorter length of subsequent stay (median 5.86 vs 4.61 days) compared to the previous influenza epidemic. In addition, 430 patient-days of unnecessary isolation have been prevented within a time span of 18 weeks. Roughly estimated savings were almost 400,000 euros.

Conclusion. We recommend that hospitals explore possibilities for improving patient flow during an influenza epidemic.

KEY WORDS

Clinical pathway, emergency department, epidemic, influenza, point-of-care-testing

BACKGROUND

Influenza viruses cause acute respiratory infection (ARI), which is self-limiting in most patients but can cause severe illness in high-risk populations. The seasonal influenza epidemic poses a significant burden on hospitals, both in terms of capacity and costs.¹ A major concern during the peak season is isolation of influenza-suspected or influenza-positive patients in single rooms, as prescribed by infection control guidelines.² Shortening test turnaround time could decrease unnecessary isolation measures and improve emergency department (ED) and hospital patient flow. Clinical chemistry point-of-care testing (POCT) was shown to reduce ED patient time and treatment delays and increase patient discharge rates.³ However, microbiological POCT has not yet been broadly implemented. The first clinical studies on influenza POCT have recently been published, reporting safety and reproducibility.⁴⁻⁷ To increase efficiency of patient care, we decided to implement a temporary clinical pathway during the 2017-2018 influenza season at the Jeroen Bosch Hospital (JBH), ’s Hertogenbosch, The Netherlands (figure 1A). A polymerase chain reaction (PCR)-based POCT for influenza A/B with a turnaround time of 20 minutes was placed at the ED and microbiology laboratory reception desk and operated by nurses and receptionists. In parallel, a separate ward with 15 beds for influenza-positive patients was established to increase efficiency of infection control by enabling cohort nursing and thus, more efficient
medical care. In this article we aim to describe our experience in implementing this clinical pathway.

**MATERIALS AND METHODS**

**Ethical approval**
Due to the retrospective and anonymous nature of this study, ethical review was waived by the Ethical Committee Brabant (no. NW2018-15).

**Setting**
The JBH is a teaching hospital with 575 beds. The ED is equipped with 12 beds that are suitable for influenza-suspected patients. In the Netherlands, free influenza vaccination is available for people over 60 years of age, people with chronic diseases, and health care workers. Vaccine coverage was and 15% and 19% for healthcare workers in the JBH during the epidemics of 2016-2017 and 2017-2018, respectively.

**PCR tests**
The Cobas Liat system is a PCR-based test for a single sample with a turnaround time of 20 minutes and approximately two minutes hands-on time (Cobas Liat, Roche Molecular Diagnostics, Mannheim, Germany). We used the combined influenza A/B/RSV assay; RSV is not included in the present study. Prior to commissioning the test, a laboratory validation process was performed using 14 clinical samples and 10 samples from a proficiency testing panel. The test results were compared to a Panther Fusion influenza A/B/RSV test (Hologic, Zaventem, Belgium) as well as in-house PCRs. Both commercial systems were more sensitive compared to the in-house PCRs (in-house 72%, Panther 83%, Liat 94% of positive test samples detected; see Supplementary Materials). During the 2016-2017 influenza epidemic, the standard of care was a laboratory-developed real-time PCR to detect influenza A/B on the BD MAX System (Becton Dickinson, Erembodegem, Belgium).

**Clinical implementation and training**
Six key users (three microbiology technicians and three ED nurses) were trained by Roche, after which ED nursing staff (n = 50) and receptionists (n = 5) were trained by the technician key users. Training included a Microsoft PowerPoint presentation, a pipetting exercise, running a demo sample, and a clinical sample. Further details are provided in the Supplementary Materials.

**Samples**
Two nose-throat (NT) swabs in Eswab medium (Copan Diagnostics, Brescia, Italy) were collected from each ED patient fulfilling the case definition: temperature ≥ 38.0 °C and symptoms of acute respiratory tract infection. One swab was used for POCT at the microbiology reception desk or ED, depending on time and day: during office hours, influenza testing was performed by laboratory receptionists; during weekends and nightshifts, ED nurses performed the test. The second NT swab was used for a confirmatory Panther Fusion test at the laboratory. Samples were stored at room temperature until collection during the next day of business. We considered the sensitivity of the PCR test to detect respiratory viruses using NT swabs as acceptable based on a number of studies including hundreds of patients. As available literature did not report inferior test performance of the Cobas Liat POCT in daily hospital practice, we decided to perform pairwise testing on a limited number of samples, followed by random pairwise testing (total n = 121). In case of a discrepant test result (one NT swab positive, while the other NT swab from the same patient was negative), the two swabs were reciprocally tested.

**Temporary influenza ward**
A separate ward was set up for all influenza-positive patients, except for those requiring special care at another ward (e.g., intensive care, cardiac care, haematology, oncology, or children’s ward; other types of patients were eligible for admission to the influenza ward). A capacity of
15 beds was calculated based on numbers of the 2016-2017 influenza season. Patients were admitted into single rooms if available; if not, they were admitted in cohort nursing according to influenza type A or B. In accordance with the number of days that patients have to be nursed in isolation, these patients were either dismissed or moved to another ward after five days, a rule that was strictly adhered to. A weekly multidisciplinary gathering (attending geriatrics doctor, ward nurse, planning nurse, manager, pulmonologist, internal medicine specialist, clinical microbiologist, infection control nurse) was set up to evaluate the process and adjust if necessary. The pathway including POCT and influenza ward was operational as soon as logistically possible after the start of the influenza season, which was on January 8th, 2018.

Statistics
Data were retrospectively collected for the influenza epidemics of 2016-2017 and 2017-2018 according to the national crossing of epidemiologic thresholds (week 48, 2016 - week 10, 2017 and week 50, 2017 - week 15, 2018). Data were gathered from the electronic patient record system Hix (ChipSoft), and the laboratory information system MOLIS (CompuGroup Medical). Only patients admitted via the ED were included in the analyses. Data including all patients is presented in the Supplementary Materials. Analyses were performed using R studio built under R version 3.3.3 (R Foundation for Statistical Computing, Vienna, Austria). A p-value of < 0.05 was considered to be statistically significant. Normal distribution of each data set was evaluated using a Shapiro-Wilk test. All data was nonparametric and analysed using a Mann-Whitney U-test; results are presented as median [interquartile range (IQR)].

Cost analysis
A rough estimate of the costs of this clinical pathway is based on the costs of laboratory and clinical aspects as well as costs based on the of length of stay, the number of hospitalisations of influenza-positive patients and the number of unnecessary isolations during the 2017-2018 season compared to the previous. Details are provided in the Supplementary Materials.

RESULTS
The Dutch National Institute for Public Health and the Environment (RIVM) reported an influenza epidemic lasting 15 weeks in 2016-2017 and 18 weeks in 2017-2018, with a 20-year average of nine weeks in the Netherlands. During the entire 2016-2017 season, influenza A(H3N2) dominated and influenza A(H1N1)pdm09 and B were only sporadically detected. The 2017-2018 epidemic was dominated by influenza B (Yamagata lineage) with an increase in influenza A (H3N2) and (H1N1)pdm09 during the second half of the epidemic (table 1 and figure 1B): in our hospital 100% influenza A was detected in 2016-2017 vs 36% influenza A in 2017-2018. Vaccine effectiveness was comparable in 2016-2017 and 2017-2018 (47% vs
Table 1. Comparison of patients admitted via the ED during influenza seasons 2016-2017 and 2017-2018 at JBH

<table>
<thead>
<tr>
<th></th>
<th>2016-2017 (15 weeks)</th>
<th>2017-2018 (18 weeks)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ED visits (n, [patients/day])</td>
<td>8979 [87]</td>
<td>11406 [92]</td>
<td>0.004</td>
</tr>
<tr>
<td>Leading to hospital admission (n, %)</td>
<td>3480 [39%]</td>
<td>4328 [38%]</td>
<td>0.23</td>
</tr>
<tr>
<td>Influenza tests (n, [no./day])</td>
<td>591 [5]</td>
<td>1546 [11]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Positive test result (n, %)</td>
<td>189 (32%)</td>
<td>624 (40%)</td>
<td>0.0003</td>
</tr>
<tr>
<td>Time from ED presentation to sample collection (minutes, median [IQR])</td>
<td>194 [116-338]</td>
<td>47 [21-124]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Time from sample collection to result (minutes, median [IQR])</td>
<td>1094 [782-1317]</td>
<td>62 [49-120]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Time on ED, all patients (hour, median [IQR])</td>
<td>2.65 [1.7-3.78]</td>
<td>2.73 [1.77-3.9]</td>
<td>0.005</td>
</tr>
<tr>
<td>Time on ED, all influenza-tested patients (hour, median [IQR])</td>
<td>3.75 [3.03-4.67]</td>
<td>3.72 [3.97-4.72]</td>
<td>0.51</td>
</tr>
<tr>
<td>Time on ED, all influenza-positive patients (hour, median [IQR])</td>
<td>3.83 [3.15-4.57]</td>
<td>3.63 [2.9-4.35]</td>
<td>0.028</td>
</tr>
<tr>
<td>Influenza-positive patients (n)</td>
<td>189</td>
<td>624</td>
<td>0.003</td>
</tr>
<tr>
<td>Age (median, IQR)</td>
<td>76 [67-84]</td>
<td>72 [58-82]</td>
<td>0.0001</td>
</tr>
<tr>
<td>Admitted to hospital (n, %)</td>
<td>172 (91%)</td>
<td>156 (70%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>• Admitted to influenza ward (n, %)</td>
<td>N/A</td>
<td>221 (49%)</td>
<td>N/A</td>
</tr>
<tr>
<td>• Admitted to ICU (n, %)</td>
<td>11 (6%)</td>
<td>21 (5%)</td>
<td>0.37</td>
</tr>
<tr>
<td>Length of hospital stay (days, median [IQR])</td>
<td>5.86 [4.01-11.27]</td>
<td>4.61 [2.72-7.96]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Bacterial or fungal superinfection (n, %)</td>
<td>21 (10%)</td>
<td>81 (14%)</td>
<td>0.17</td>
</tr>
<tr>
<td>Influenza A-positive patients (n, %)</td>
<td>189 (100%)</td>
<td>224 (36%)</td>
<td></td>
</tr>
<tr>
<td>Admitted to hospital (n, %)</td>
<td>172 (91%)</td>
<td>156 (70%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>• Admitted to influenza ward (n, %)</td>
<td>N/A</td>
<td>77 (49%)</td>
<td>N/A</td>
</tr>
<tr>
<td>• Admitted to ICU (n, %)</td>
<td>11 (6%)</td>
<td>5 (3%)</td>
<td>0.18</td>
</tr>
<tr>
<td>Length of hospital stay (days, median [IQR])</td>
<td>5.86 [4.01-11.27]</td>
<td>3.91 [2.61-7.48]</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Bacterial or fungal superinfection (n, %)</td>
<td>21 (10%)</td>
<td>26 (12%)</td>
<td>0.55</td>
</tr>
<tr>
<td>Admitted influenza-positive patients that received one or more doses antibiotics* (n, %)</td>
<td>99 (58%)</td>
<td>206 (45%)</td>
<td>0.006</td>
</tr>
<tr>
<td>Of which, received at the ED (n, %)</td>
<td>71 (41%)</td>
<td>157 (35%)</td>
<td>0.11</td>
</tr>
<tr>
<td>Admitted influenza-negative patients that received one or more doses antibiotics* (n, %)</td>
<td>229 (61%)</td>
<td>364 (49%)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Of which, received at the ED (n, %)</td>
<td>162 (43%)</td>
<td>287 (39%)</td>
<td>0.14</td>
</tr>
<tr>
<td>Admitted influenza-positive patients that received one or more doses oseltamivir* (n, %)</td>
<td>15 (9%)</td>
<td>50 (11%)</td>
<td>0.40</td>
</tr>
<tr>
<td>Of which, received at the ED (n, %)</td>
<td>11 (6%)</td>
<td>45 (10%)</td>
<td>0.17</td>
</tr>
<tr>
<td>Admitted influenza-negative patients that received one or more doses oseltamivir* (n, %)</td>
<td>20 (5%)</td>
<td>4 (0.6%)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Of which received at the ED (n, %)</td>
<td>16 (4%)</td>
<td>3 (0.4%)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

Data are analysed using a Mann-Whitney U-test for nonparametric data. During influenza season 2016-2017, only influenza A was detected. *Antibiotics include only amoxicillin and cefuroxime, the empiric antibiotics for community-acquired pneumonia in our hospital.

ED = emergency department; IQR = interquartile range; ICU = intensive care unit
During the 2017-2018 influenza season, a high number of elderly people with pneumonia was registered nationally as compared to the previous year, as well as a sharp increase in mortality. The vaccination rate of employees on the influenza ward was 74%, whereas the same department (then Geriatrics) in 2016 had a vaccination rate of 47%. During weekly gatherings, all disciplines involved declared to endorse the implementation of the clinical pathway.

Antibiotic use was significantly reduced in 2017-2018 compared to 2016-2017, at a similar rate for both influenza-positive and -negative patients (table 1). Oseltamivir use however was significantly lower for admitted influenza-negative patients (5% in 2016-2017 vs 0.6% in 2017-2018, p < 0.0001), most of which was accounted for by oseltamivir that was started in the ED (4% in 2016-2017 vs 0.4% in 2017-2018; p < 0.0001). For influenza-positive patients, no significant difference in oseltamivir use was observed between the 2016-2017 and 2017-2018 seasons (9% vs 11%, respectively; p = 0.4). The rate of bacterial or fungal superinfection (defined as positive culture of respiratory tract material or positive pneumococcal antigen test) was not significantly different either in admitted influenza patients during the 2016-2017 and 2017-2018 seasons (10% vs 14%, respectively; p = 0.17; for influenza A-positive patients only, 10% vs 12%, p = 0.55).

The vaccination rate of employees on the influenza ward was 74%, whereas the same department (then Geriatrics) in 2016 had a vaccination rate of 47%. During weekly gatherings, all disciplines involved declared to endorse the implementation of the clinical pathway.

**Costs**

Estimated costs of the laboratory aspects of the clinical pathway were 73,822 euros (personnel 43,822; technical costs 30,000 euros). The costs of the laboratory aspects of the clinical pathway are 73,822 euros (personnel 43,822; technical costs 30,000 euros).

**Figure 1C. Influenza-positive patients admitted to the influenza ward and other clinical wards during 2017-2018 epidemic.**

ICU = intensive care unit; CCU = cardiac care unit; ONCO = oncology
DISCUSSION

Overall, our hospital had a positive experience with the implementation of the clinical pathway for influenza. Test performance was good and turnaround times significantly reduced. Comparing the epidemics of 2016-2017 and 2017-2018, ED patient-time was slightly decreased for influenza-positive patients, even while an increase for all ED patients was observed. A lower percentage of influenza-positive patients was admitted, which was also true for patients with a negative influenza test, but not for all ED patients. Increased ED discharge rates could be due to faster influenza test results, available for a larger proportion of presenting patients; the prevailing viruses are unlikely to be responsible, since the 2017-2018 season appeared to be more severe with a higher incidence of pneumonia compared to the previous year and higher mortality was observed. Length of stay of both influenza A and B-positive patients was shorter compared to the previous season, which could be related to more efficient clinical decision making and the short-stay nature of the influenza ward. A strong reduction in unnecessary isolation was accomplished, which is an important factor in improving hospital patient flow.

The reductions in admissions, length of stay, and unnecessary isolation combined were roughly estimated to have saved 397,030 euros. To gain better insight into the costs and savings from a healthcare provider perspective, a more sophisticated analysis including costs associated with additional or avoided diagnostics is required. We do not expect this to strongly alter the result: the number of additional tests related to respiratory tract infection was not significantly different in 2016-2017 compared to 2017-2018 (sputum culture in 31% vs 30% of patients and Legionella and Streptococcus pneumoniae antigen tests both in 4% vs 4% of patients, respectively). Our data do not indicate that a more severely ill selection of influenza-positive patients was admitted in 2017-2018 compared to 2016-2017: The percentage of superinfections and ICU admissions was not different; a lower percentage of patients received antibiotics and the length of stay was shorter.

In setting up a clinical pathway for influenza, several aspects should be considered. The single-sample capacity of the POCT can be a disadvantage if many patients with respiratory disease present at once. It proved useful to transfer the second POCT from the microbiology reception desk to the ED during peak moments. Near the end of the epidemic, it was considered better to not include fever criterion into the case definition, but only acute respiratory tract infection, since cases might be missed. Retrospectively, the 15-bed influenza ward should have been twice as large during the peak season. The estimation of the required capacity was calculated based on previous seasons’ numbers: the discrepancy could be due to both a different algorithm for and way of testing, and the epidemic in general being more severe compared to the previous year.

Few studies have been published on PCR-based influenza POCT in daily practice. Gibson et al. found 99.6% and 99.7% percent positive agreement for the Cobas Liat Influenza test compared to another PCR-based test in 1361 nasopharyngeal swabs (both primary care and ED). Trabattoni et al. used the Alere i Influenza A&B POCT in 132 ED patients and found reduced hospitalization rates and a reduced number of additional diagnostic tests compared with routine testing, but no differences in prescription of antibiotics. In contrast with the modest reduction in ED patient-time we observed, this study found a strong reduction from approximately six hours to four hours; however, in our study ED patient-time was already four hours before implementation of POCT. Brendish et al. performed the only randomized controlled trial so far, using the FilmArray Respiratory Panel, which includes 17 viruses and 3 bacteria. They found a reduced length of hospital stay for patients assigned to POCT (n = 362, mean 5.7 days) versus routine care (n = 358, mean 6.8 days). This observation was most pronounced among patients with exacerbations of airway disease, in whom also a significant reduction of antibiotic duration was reported. Patient time in ED was not reported; mean POCT turnaround time was 2.3 hours. Influenza POCT was shown to provide overall cost savings due to changes in physician decision making. To the best of our knowledge, this is one of the first reports on implementation of a clinical pathway for influenza, focusing not only on the POCT itself but on all aspects involved in clinical care for influenza patients during an epidemic. This study has a number of limitations. Due to its retrospective nature, no causal relationships can be inferred. Circulating viruses and severity of both epidemics could affect many of the reported values. The slightly younger age of influenza-positive patients could be a confounder. While in 2017-2018, the case
definition for testing was strictly adhered to, it is possible that in 2016-2017 some influenza-positive admitted patients remained undetected, rendering our comparison incomplete.

Overall, implementation of the clinical pathway for influenza patients proved a success in terms of practical and logistical execution in a multidisciplinary setting. Based on our results, the clinical pathway has likely improved patient flow, possibly leading to a lower percentage of admissions and shorter length of stay. Moreover, it has likely led to a significant reduction in costs. We would recommend hospitals with settings similar to ours to explore possibilities in improving patient flow during the influenza epidemic. Our data may not be applicable to, for example academic hospitals, which have a very different type of patient population, when commissioning a different POCT, when plenty of single rooms are available, or when the laboratory is open 24/7. Further research is needed to dissect the full impact of implementing an influenza clinical pathway, but the first results are promising.

ACKNOWLEDGEMENTS

The authors would like to thank all involved JBH employees for all the effort they put into this project, especially Kathelijn Geraats, Marcel Sterks, Jeroen Schellekens, Monic Janssen, Jaap Kroon, Karin Zeegers (key users of the Cobas Liat system); John de Laat, Mieke van Bergen, Natasja van Duijvendijk, Karin Oostelbos (Head of Unit of the Emergency Department, Influenza Ward and Microbiology Department, respectively). Peter Wever (local responsible investigator), Saskia Walbeek, Eline Lohstroh (quality officers), Eric Smits, Theo van Well (department managers), Marleen Henskens and colleagues of the Infection Control team, the Management information team, Jens Verhagen and colleagues of the communication department, all planning nurses under supervision of Yvonne Kouwenberg and all the nurses, doctors, and laboratory personnel who contributed to making this influenza season a success in our hospital.

PREVIOUS PRESENTATION OF DATA

Part of the data from this paper was presented as a poster at the Scientific Spring Meeting of the Dutch Society for Microbiology (NVMM/KNVM), Papendal, The Netherlands, March 2018. In addition, part of the data was published as a short, non-scientific report in Dutch in Medisch Contact, section ‘Beleid’, October 31st, 2018.

DISCLOSURES

All authors declare no conflicts of interest. No funding or financial support was received.

* For the Supplementary Materials, please contact the corresponding author.

REFERENCES